Wholesale modulation of B-ALL cell state and phenotype aligns with previous observations in cell line models and patients, where CD19 loss was accompanied by CD22 downregulation18–22 and loss of both antigens is reversible17,23. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.